Biofrontera Inc. (BFRI)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $0.83
- As of
Kresmion compiles this page from BFRI's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Biofrontera Inc. (BFRI): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
See the full BFRI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BFRI on one page. Preview it with sample data, then open it live with a free account.
Preview the BFRI dossierActive events for BFRI
- mediumEarnings above estimates
Q2-2026: Beat consensus by 53.3%, EPS $-0.05 vs $-0.1071 estimate
- medium13F: new position
CITADEL ADVISORS LLC new position in BFRI
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +742% to BFRI (2026Q2)
- mediumEarnings below estimates
Q2-2025: Missed consensus by 33.1% - EPS $-0.57 vs $-0.4284 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 142.8% - EPS $0.483 vs $0.1989 estimate
FREE, NO ACCOUNT
Every event on BFRI, as it fires
You are seeing 5 of 6 events recorded on BFRI since 2026-05-30.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
BFRI positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 09077D209 · 2026Q2 | $149K | 0.00% |
| CITADEL ADVISORS LLC FundCUSIP 09077D209 · 2026Q2 | $99K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BFRI
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
BFRI's 10-Q filed Aug 13, 2026 states:
Management believes that these conditions raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on BFRI
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in BFRI on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on BFRI in the last 180 days.
Upstream: SEC EDGAR filings for BFRI
Kresmion, "Biofrontera Inc. (BFRI) institutional holdings and SEC filings", data as of 2026-09-14, https://kresmion.com/research/BFRI. Upstream data: SEC EDGAR filings for BFRI.
Link to this data (HTML):
<a href="https://kresmion.com/research/BFRI">Biofrontera Inc. (BFRI) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow BFRI on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to BFRI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.